ClinicalTrials.Veeva

Menu

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials (REALiTEC/TAL)

Janssen (J&J Innovative Medicine) logo

Janssen (J&J Innovative Medicine)

Status

Enrolling

Conditions

Relapsed/Refractory Multiple Myeloma (RRMM)

Treatments

Other: Talquetamab
Other: Teclistamab

Study type

Observational

Funder types

Industry

Identifiers

NCT06285318
64007957MMY4004

Details and patient eligibility

About

The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.

Enrollment

280 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Have a documented diagnosis of multiple myeloma
  • Received the first dose of teclistamab on or before 31 December 2022, regardless of the duration of teclistamab treatment (REALiTEC cohort) OR Received the first dose of talquetamab on or before 31 December 2023, regardless of the duration of talquetamab treatment (REALiTAL cohort). Participants who received both teclistamab & talquetamab can be included in both REALiTEC and REALiTAL cohorts
  • Received at least one dose of teclistamab/talquetamab
  • Provision of a patient-signed informed consent form (ICF), or an ICF waiver for deceased patients as applicable based on country/site-specific requirements

Exclusion criteria

  • To be excluded from REALiTEC cohort if received teclistamab as part of an interventional clinical trial
  • To be excluded from REALiTAL cohort if received talquetamab as part of an interventional clinical trial

Trial design

280 participants in 2 patient groups

Participants with Relapsed/Refractory Multiple Myeloma (RRMM): Teclistamab Cohort
Description:
Participants with RRMM who received at least one dose of teclistamab outside of clinical trials on or before 31 December 2022 will be enrolled in the study. The data available from the medical records of each enrolled participant will be the collected to describe the use of teclistamab.
Treatment:
Other: Teclistamab
Participants with RRMM: Talquetamab Cohort
Description:
Participants with RRMM who received at least one dose of talquetamab outside of clinical trials on or before 31 December 2023 will be enrolled in the study. The data available from the medical records of each enrolled participant will be collected to describe the use of talquetamab.
Treatment:
Other: Talquetamab

Trial contacts and locations

25

Loading...

Central trial contact

Study Contact

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems